Progress in Public Health: HIV, Tuberculosis, and Malaria

Join the Life Sciences Alumni Group in the Bay Area for this presentation on HIV, Tuberculosis, and Malaria with Dr. Paul A. Volberding, (AB'71) MD and Roland Gosling, MD PhD.

Cost: $35.00 to cover cost of catering
WALK-INS WELCOME
CLICK HERE TO REGISTER


AIDS, Tuberculosis and Malaria are among the serious diseases representing significant public health threats. Today, millions of HIV positive people are living healthy and productive lives, yet 1 out of 2 people infected with HIV does not know their status. Tuberculosis is now the leading cause of death for those living with HIV. While highly effective treatments for malaria exist, drug resistant Plasmodium strains are emerging and mosquito host resistance to commonly used insecticides is on the rise. It is time to eliminate AIDS, Tuberculosis and Malaria as global health threats. 

 

Speaker Biographies

     Paul A. Volberding, MD, is a professor in the Department of Medicine and director of the Center for AIDS Research at the University of California, San Francisco (UCSF) and the Gladstone Institute of Virology and Immunology; and served until 2012 as vice chair of the Department of Medicine. He was appointed director of the AIDS Research Institute at UCSF and director of research for Global Health Sciences in 2012. Dr. Volberding served as director of the Positive Health Program at San Francisco General Hospital (SFGH) for 20 years. He received his undergraduate and medical degrees at the University of Chicago and the University of Minnesota, respectively, and finished training at the University of Utah and at UCSF, where he studied for two years as a research fellow in the virology laboratory of Dr. Jay Levy, later a co-discoverer of HIV.

     Dr. Volberding’s professional activities centered for many years at SFGH, where he established a model program of AIDS patient care, research, and professional education. His research career began with investigations of HIV-related malignancies, especially Kaposi's sarcoma. His primary research focus, however, shifted to clinical trials of antiretroviral drugs. He has been instrumental in testing many compounds, but is best known for groundbreaking trials establishing standards of care for the use of zidovudine in asymptomatic HIV infection and for continuous service on the two major guidelines panels for antiretroviral therapy.

    Roland Gosling MD, PhD Dr. Roland (Roly) Gosling, BmedSci, BM, BS, MSc, PhD, is Associate Professor of Epidemiology and Biostatistics, Lead of the Malaria Elimination Initiative at the UCSF Global Health Group since 2011. The Malaria Elimination Initiative is an influential “Action Tank” that supports malaria control programs of low endemic countries reach malaria elimination and prevent reintroduction of malaria. The Malaria Elimination Initiative offers technical support to countries for surveillance and response activities, malaria risk assessments and advocacy tools to help raise financing. In addition the Malaria Elimination Initiative supports regional efforts for malaria elimination through the Asia Pacific Malaria Elimination Network (APMEN) and the Elimination 8 in southern Africa. Globally the Malaria Elimination Initiative provides a forum to discuss malaria elimination including hosting consensus making meetings over specific topics such as the use of drugs and vaccines for malaria elimination, supports global decision making bodies, like the World Health Organization and keeps malaria elimination in the eyes of stakeholders in order to maintain the necessary financing to get the job done. 

     Roly trained as a medical doctor at The University of Nottingham in the UK and later at the London School of Hygiene and Tropical Medicine for his MSc and PhD. He worked in west Africa at the Medical Research Council laboratories in The Gambia and spent 7 years working in Tanzania, firstly as faculty for University College London and later for the London School of Hygiene and Tropical Medicine. During this time he worked on clinical trials for malaria drugs and prevention and tuberculosis treatment. He has a broad interest in public health in developing countries and specific interests in strategies to reduce malaria transmission, how to detect falls in transmission and how to monitor malaria in low endemic or post elimination settings. 


 If you wish to attend and cannot register online, please email Todd Slaby (address below).

Event Contacts
Todd Slaby
todd.b.slaby@gmail.com
510.672.1109
Staff Liaison

affinity@uchicago.edu
+1.773.702.2158